| scholarly article | Q13442814 |
| P50 | author | John R. Graybill | Q109648584 |
| Laura K. Najvar | Q115923764 | ||
| Rosie A Bocanegra | Q115923770 | ||
| P2093 | author name string | Robert A Larsen | |
| Steve Hernandez | |||
| P2860 | cites work | Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis | Q33980836 |
| Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. | Q34143326 | ||
| Oral azole drugs as systemic antifungal therapy | Q40796244 | ||
| Compounds active against cell walls of medically important fungi | Q40889532 | ||
| Comparison of caspofungin and amphotericin B for invasive candidiasis | Q44255071 | ||
| A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute | Q72741418 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | candidiasis | Q273510 |
| fluconazole | Q411478 | ||
| P304 | page(s) | 2373-2375 | |
| P577 | publication date | 2003-07-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Addition of caspofungin to fluconazole does not improve outcome in murine candidiasis | |
| P478 | volume | 47 |
| Q36201569 | Antifungal combination therapy: clinical potential |
| Q41835779 | Assessment of the in vitro kinetic activity of caspofungin against Candida glabrata |
| Q33805542 | Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis |
| Q38586680 | Caspofungin: Pharmacodynamics, pharmacokinetics, clinical uses and treatment outcomes |
| Q35537846 | Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis |
| Q76381447 | Combination antifungal therapy |
| Q36895652 | Combination antifungal therapy: the new frontier |
| Q36960092 | Combination antifungals: an update |
| Q36011378 | Combination treatment of invasive fungal infections |
| Q45310211 | Cryptococcus neoformans: the model organism for yeast antifungal drug susceptibility testing |
| Q37718385 | Echinocandin pharmacodynamics: review and clinical implications. |
| Q36458402 | Emerging echinocandins for treatment of invasive fungal infections |
| Q37489291 | In vitro activities of voriconazole in combination with three other antifungal agents against Candida glabrata |
| Q35179937 | Mechanism underlying renal failure caused by pathogenic Candida albicans infection |
| Q37625016 | Need for early antifungal treatment confirmed in experimental disseminated Candida albicans infection. |
| Q39954432 | Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations |
| Q28487653 | Posaconazole exhibits in vitro and in vivo synergistic antifungal activity with caspofungin or FK506 against Candida albicans |
| Q35917383 | Recent advances in antifungal pharmacotherapy for invasive fungal infections |
| Q37568916 | Sequential therapy with caspofungin and fluconazole for Candida albicans infection |
| Q35587115 | Status of combination therapy for refractory mycoses |
| Q35828187 | Toward more effective antifungal therapy: the prospects of combination therapy. |
| Q37255172 | Treatment of invasive candidiasis in immunocompromised pediatric patients |
Search more.